Amgen Inc (AMGN) operating KPIs
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)
Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%
Amgen segment Expense Disaggregation (Note 2) — Manufacturing Cost of Sales Excluding Amort & Royalty ($M) ($M)
Form 10-Q / 10-K Note 2 Segment Reporting (ASC 280-10-50-26A)
Latest, Q2 2026
2,139
Period ended Jun 30, 2026
Change on a year earlier
-13.9%
2,484 in Q2 2025
History
10 quarters
Since Q1 2024
Sources
6
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Segment Expense Disaggregation (Note 2) — Manufacturing Cost of Sales Excluding Amort & Royalty ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 2,139 | -13.9% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 2,180 | -13.8% | Form 10-Q (filed 2026-05-01) ↗ |
| Q4 2025 | Dec 31, 2025 | 2,325 | -11.5% | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2025 | Sep 30, 2025 | 2,508 | -12.1% | Form 10-Q (filed 2025-11-05) ↗ |
| Q2 2025 | Jun 30, 2025 | 2,484 | -12.1% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2025 | Mar 31, 2025 | 2,528 | -10.2% | Form 10-Q (filed 2026-05-01) ↗ |
| Q4 2024 | Dec 31, 2024 | 2,627 | – | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2024 | Sep 30, 2024 | 2,852 | – | Form 10-Q (filed 2025-11-05) ↗ |
| Q2 2024 | Jun 30, 2024 | 2,825 | – | Form 10-Q (filed 2025-08-06) ↗ |
| Q1 2024 | Mar 31, 2024 | 2,814 | – | Form 10-Q (filed 2025-05-02) ↗ |
Breakdown
What makes up segment expense disaggregation (note 2) — manufacturing cost of sales excluding amort & royalty ($m)
- Segment Profit Share & Royalty Expense in Cost of Sales ($M)672 · Q2 2026
- Segment Selling & Marketing Expense ($M)1,155 · Q2 2026
- Segment General & Administrative Expense ($M)590 · Q2 2026
- Other Segment Items (Other Operating Expenses & Non-Core Items) ($M)314 · Q2 2026
- Advertising Expense ($M)–
- Restructuring Charges (legacy standalone disclosure) ($M)15 · Q4 2023
Cite this data
StockData. (2026). Amgen Segment Expense Disaggregation (Note 2) — Manufacturing Cost of Sales Excluding Amort & Royalty ($M) ($M), quarterly Q1 2024–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/seg_mfg_cogs
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.